🟠 Moderate Evidence
A common misconception about vitamin C supplementation holds that doses above 200 mg are wasted because absorption efficiency declines. However, new analysis of landmark pharmacokinetic studies reveals that while the fraction absorbed decreases at higher doses, the total milligrams absorbed continues to increase—making higher doses pharmacologically rational despite reduced efficiency per milligram.
Key takeaways
- Bioavailability of vitamin C is 100% at 200 mg but drops to 50% at 1,000 mg, according to Levine et al. (PNAS, 1996)
- Despite lower absorption efficiency, total vitamin C absorbed increases from ~200 mg at 200 mg dose to ~500 mg at 1,000 mg dose
- Immune cells concentrate vitamin C intracellularly at levels 50–100 times higher than plasma concentration, creating sustained demand for higher doses
Study at a Glance
| Source | PNAS (Proceedings of the National Academy of Sciences) |
| Study type | Controlled pharmacokinetic study with steady-state measurement |
| Sample size | N = 7 healthy men (1996); N = 15 women (2001 follow-up) |
| Population | Healthy adults initially depleted of vitamin C (<5 mg/day for 4–6 months) |
| Country | United States |
Vitamin C Absorption: Efficiency vs. Absolute Quantity
Bioavailability declines but total milligrams absorbed increases with dose, according to Levine et al. (PNAS, 1996)
Source: Levine et al., PNAS, 1996 | Georgian Medical Journal News
The Sigmoidal Absorption Curve: Why Efficiency Matters Less Than Total Intake
Levine et al.’s landmark 1996 study in PNAS enrolled seven healthy men who underwent controlled depletion (diet containing less than 5 mg vitamin C daily for 4–6 months) followed by sequential repleting doses ranging from 30 mg to 2,500 mg. Researchers measured steady-state plasma concentrations at each level, establishing the first rigorous pharmacokinetic profile in humans.
The resulting curve is sigmoidal: bioavailability remains at 100% up to approximately 200 mg, then declines systematically as doses increase. At 500 mg, absorption drops to roughly 73%; at 1,000 mg to roughly 50%; and at 1,250 mg to approximately 33%. This decline reflects two biological mechanisms: saturation of the intestinal transporter SVCT1 and increased renal excretion of unabsorbed vitamin C.
Critics of higher-dose supplementation typically cite this efficiency decline as evidence that doses above 200 mg are wasteful. However, this interpretation overlooks a fundamental pharmacological principle: declining efficiency does not equal declining efficacy in absolute terms. See our explainers on nutrient bioavailability for more on this distinction.
Absolute Absorption Increases Despite Lower Efficiency
The critical insight emerges when examining total milligrams absorbed rather than absorption percentage. At a 200 mg dose, absorption of approximately 200 mg occurs (100% efficiency). At 500 mg, approximately 365 mg is absorbed (73% efficiency). At 1,000 mg, approximately 500 mg is absorbed (50% efficiency). In every case, the total amount of vitamin C reaching circulation increases, even as the fraction per milligram consumed declines.
A follow-up 2001 study by Levine et al. in PNAS confirmed this same sigmoidal pattern in 15 women, establishing that the pharmacokinetic profile is independent of sex. This is the distinction that the vitamin C debate frequently misses: lower absorption per milligram is not equivalent to lower absolute bioavailability or clinical irrelevance.
Intracellular Demand: The Physiological Case for Higher Doses
Understanding why higher doses matter requires examining vitamin C demand on the intracellular level. Immune cells—particularly neutrophils, monocytes, and lymphocytes—actively concentrate vitamin C through the SVCT2 transporter to levels 50 to 100 times higher than plasma concentration. In healthy individuals consuming at least 100 mg daily, intracellular vitamin C concentrations reach approximately 1.5 mM in neutrophils and 3.5 mM in lymphocytes.
This enormous concentration gradient reflects biological demand: vitamin C acts as a cofactor for collagen synthesis, immune cell function, and antioxidant defense within these cells. The fact that immune cells maintain such high intracellular levels suggests that maintaining adequate plasma vitamin C availability is clinically important for immune function. Higher doses, despite reduced per-milligram efficiency, may serve this sustained intracellular demand more effectively than smaller doses.
At 1,000 mg, vitamin C bioavailability is 50%—but absolute absorption reaches ~500 mg, substantially higher than the ~200 mg absorbed from a 200 mg dose, despite the latter’s 100% efficiency.
— Levine et al., National Institutes of Health (PNAS, 1996)
What this means
Higher-dose vitamin C supplements (1,000 mg or above) deliver more total vitamin C to circulation than lower doses, despite reduced absorption efficiency. Individuals pursuing high-dose supplementation for immune support have a pharmacological rationale, though they should ensure adequate hydration and renal function to manage urinary excretion.
When counseling patients on vitamin C supplementation, distinguishing between absorption efficiency and absolute bioavailability is essential. Patients with immune compromise or specific metabolic demands may benefit from doses above 200 mg despite lower per-milligram efficiency. Consider individual renal and metabolic factors when recommending doses.
Current dietary guidelines and supplement labeling often emphasize absorption efficiency without clarifying that absolute delivery of micronutrients increases with higher doses. Public health messaging should reflect the distinction between efficiency and efficacy to prevent misleading consumers away from potentially beneficial supplementation strategies.
Frequently asked questions
Is a 1,000 mg vitamin C dose actually absorbed?
Yes. Although only 50% of a 1,000 mg dose is absorbed (compared to 100% of a 200 mg dose), the absolute amount absorbed—approximately 500 mg—exceeds what is absorbed from smaller doses. This 500 mg enters circulation and can be delivered to immune cells and tissues that actively concentrate vitamin C intracellularly.
Why do immune cells concentrate vitamin C so much higher than plasma?
Immune cells—neutrophils, monocytes, and lymphocytes—require high intracellular vitamin C concentrations to support collagen synthesis, immune signaling, and antioxidant defense during infection and inflammatory responses. The SVCT2 transporter actively pumps vitamin C into these cells against a concentration gradient, maintaining levels 50–100 times higher than blood plasma.
Does this mean everyone should take 1,000 mg daily?
Not necessarily. Optimal vitamin C intake depends on individual factors including baseline intake, immune status, renal function, and metabolic demands. The 100–200 mg daily intake used in Levine’s studies saturates immune cells in healthy individuals. However, individuals with specific immune challenges or those seeking higher absolute intake have a pharmacological rationale for higher supplemental doses.
The vitamin C absorption debate has long been framed as a simple efficiency question: if you absorb less per milligram at high doses, why take them? The answer, revealed by rigorous pharmacokinetic data, is that absolute delivery matters more than per-milligram efficiency. For individuals seeking to maximize intracellular vitamin C delivery to immune cells, doses substantially above 200 mg remain physiologically rational—provided they maintain adequate hydration and normal renal function. Future research should examine whether this higher absolute absorption translates to measurable improvements in immune outcomes during specific disease states or populations with elevated vitamin C demand. See our New Studies section for emerging vitamin C immunology research.
Source: Vitamin C absorption pharmacokinetics: Levine et al. PNAS 1996, 2001
Was this article helpful?
Disclaimer. This article is health journalism intended for general information and education. It is not medical advice and is not a substitute for professional diagnosis or treatment. Always consult a qualified healthcare provider about your individual circumstances. Full disclaimer →
Related Coverage
Editorial standards. This article was produced under the GMJ News editorial process, with oversight by the GMJ Editorial Board. Our editorial process. Spotted an error? Contact the editorial team.
